Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Encephalopathy - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H2 2016, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Encephalopathy. Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Encephalopathy Overview 7 Therapeutics Development 8 Pipeline Products for Encephalopathy - Overview 8 Pipeline Products for Encephalopathy - Comparative Analysis 9 Encephalopathy - Therapeutics under Development by Companies 10 Encephalopathy - Therapeutics under Investigation by Universities/Institutes 11 Encephalopathy - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Encephalopathy - Products under Development by Companies 14 Encephalopathy - Products under Investigation by Universities/Institutes 15 Encephalopathy - Companies Involved in Therapeutics Development 16 Celgene Corp 16 Chiesi Farmaceutici SpA 17 Fera Pharmaceuticals LLC 18 GW Pharmaceuticals Plc 19 JS Genetics Inc 20 ProThera Biologics Inc 21 SciFluor Life Sciences LLC 22 Turing Pharmaceuticals AG 23 Zambon Company SpA 24 Encephalopathy - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 Alda-1 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 diazoxide - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 GWP-42003 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 melatonin - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 ORP-006 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 phenobarbitol sodium - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 SF-0034 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 TRP-005 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 TRP-601 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 TUR-004 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 ZP-053 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Encephalopathy - Product Development Milestones 50 Featured News & Press Releases 50 Nov 16, 2015: Turing Initiates Dosing in Phase I Clinical Trial of TUR 004 for Epileptic Encephalopathies 50 Oct 23, 2015: Turing Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application and Fast Track Designation for TUR-004 50 Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51 Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development for Encephalopathy, H2 2016 8 Number of Products under Development for Encephalopathy - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Encephalopathy - Pipeline by Celgene Corp, H2 2016 16 Encephalopathy - Pipeline by Chiesi Farmaceutici SpA, H2 2016 17 Encephalopathy - Pipeline by Fera Pharmaceuticals LLC, H2 2016 18 Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H2 2016 19 Encephalopathy - Pipeline by JS Genetics Inc, H2 2016 20 Encephalopathy - Pipeline by ProThera Biologics Inc, H2 2016 21 Encephalopathy - Pipeline by SciFluor Life Sciences LLC, H2 2016 22 Encephalopathy - Pipeline by Turing Pharmaceuticals AG, H2 2016 23 Encephalopathy - Pipeline by Zambon Company SpA, H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
